Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.57 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.56 |
| ▸ | GRM5 | P41594 | 6/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239831 | 0.83 | NAMPT (0.66) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL2358167 | 0.81 | GPR119 (0.59) | GPR119GRM1GRM5PDK4NAMPT | |
| SCHEMBL19989639 | 0.81 | NAMPT (0.67) | GRM1GRM5PDK4NAMPTBTK | |
| SCHEMBL1198787 | 0.80 | PDE10A (0.56) | GPR119GRM1GRM5PDK4NAMPT | |
| SCHEMBL8610129 | 0.79 | GRM1 (0.56) | GRM1GRM5PDK4NAMPTBTK | |
| SCHEMBL31379931 | 0.79 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTBTK | |
| SCHEMBL31705807 | 0.79 | GPR119 (0.56) | GPR119GRM1GRM5PDK4NAMPT | |
| SCHEMBL31705435 | 0.79 | GPR119 (0.56) | GPR119GRM1GRM5PDK4NAMPT | |
| SCHEMBL23408331 | 0.78 | GRM1 (0.53) | GPR119GRM1GRM5PDK4NAMPT | |
| SCHEMBL22290520 | 0.78 | GRM1 (0.53) | GPR119GRM1GRM5PDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | GPR119 1331/4885GRM1 363/4885GRM5 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.